All In Biotech

Drug Trial Radar · NCT05544227

Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer

Immunotherapy Regimen Given After Targeted Local Cryolysis (TLC) for Patients With Advanced/Metastatic Castration-resistant Prostate Cancer (mCRPC) OR Those With Metastatic Prostate Cancer Who Refused Hormone Therapy and Chemotherapy.

Last checked: Nov 19, 2026Latest source record: Jul 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

15

Actual

Start

Feb 1, 2023

Primary completion

Dec 10, 2024

Study completion Jun 1, 2025

Sponsor

Lead sponsor
Williams Cancer FoundationAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Syncromune, Inc.
First posted
Sep 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

SV-102 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immuno-pharmacologic effects.

Conditions

  • Metastatic Castration-resistant Prostate Cancer

Interventions

  • SV-102Drug

    SV-102 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immunopharmacologic effects.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.Time frame: Baseline through 30 days after end-of-treatment
  2. Number of participants with deathsTime frame: Baseline through 30 days after end-of-treatment
  3. Number of participants with treatment-emergent SAEs and AEsTime frame: Baseline through 30 days after end-of-treatment
  4. Assessment of laboratory values.Time frame: Baseline through 30 days after end-of-treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital Diomed

    Mexico City, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.